Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement

Dow Jones

Aug 18

By Connor Hart

Adaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026.

Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products.

As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology.

Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement.

Shares of Adaptive fall 1.7% in premarket trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

August 18, 2025 08:53 ET (12:53 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2560190018"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2560190018\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2560190018?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-18 20:53","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2560190018","market":"sg","top_or_hot":-1,"title":"Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n</p>\n<p>\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n</p>\n<p>\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n</p>\n<p>\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n</p>\n<p>\n  Shares of Adaptive fall 1.7% in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Adaptive Biotechnologies, Genentech to Terminate Strategic Agreement</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAdaptive Biotechnologies, Genentech to Terminate Strategic Agreement\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-18 20:53</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ADPT\">Adaptive Biotechnologies</a> said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n</p>\n<p>\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n</p>\n<p>\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n</p>\n<p>\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n</p>\n<p>\n  Shares of Adaptive fall 1.7% in premarket trading. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 18, 2025 08:53 ET (12:53 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4121","symbol_name":"生命科学工具和服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2560190018","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2560190018","pubTimestamp":1755521580,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Adaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026.Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products.As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology.Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement.Shares of Adaptive fall 1.7% in premarket trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4121":"生命科学工具和服务","BK4007":"制药","RHHBY":"罗氏控股","ADPT":"Adaptive Biotechnologies Corp","03165":"华夏欧优股对冲"},"translate_title":"Adaptive Biotechnologies与基因泰克终止战略协议","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03165":0.6,"ADPT":0.9,"RHHBY":0.9},"content_text":"By Connor Hart \n\n\n \n\n\nAdaptive Biotechnologies said Monday that its strategic collaboration and licensing agreement with Genentech will be terminated, effective Feb. 9, 2026. \n\n\n  Adaptive and Genentech, a unit of Roche, entered the agreement in 2018 to collaborate on research and development of certain cancer cell therapy products. \n\n\n  As a result of the termination, the companies will wind down all activities under the agreement. Upon its closing, Adaptive said it will be released from exclusivity obligations regarding cell therapies in oncology. \n\n\n  Adaptive said it expects to recognize $33.7 million in non-cash revenue during the back half of the year from the remaining amortization of the cash consideration received under the agreement. \n\n\n  Shares of Adaptive fall 1.7% in premarket trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 18, 2025 08:53 ET (12:53 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"corporation","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}